ARCHIVES

Phase III Regorafenib Trial Meets PFS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Kimes, Lenfant, To Retire

July 11, 2003

In Brief: Ford Named Acting Deputy Director, DCPC; Foundation Leads Oncology Administrators

June 3, 1994

ODAC Unanimously Rejects Melblez, Citing Lower Survival

May 17, 2013

National Coalition Dinner Honors Cancer Program Founders, Advocates, And Cancer Survivors

March 6, 1992

Advocacy: NCCS, ASCO Petition FDA To Set Standards For Expanded Access Programs.

April 14, 2006

First Compound From New In Vitro Screening to Enter Clinical Trials

December 5, 1986